 Proactive Investors USA & Canada | Spectrum Pharmaceuticals Announces Outstanding ZEVALIN(R) Clinical Data In ... MarketWatch (press release) The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a ... Spectrum Pharmaceuticals Announces Outstanding ZEVALINĀ® Clinical Data In ... New clinical data for ZEVALIN Injection for intravenous use presented at 17th ... |
